标题
Targeting of NMDA receptors in new treatments for schizophrenia
作者
关键词
-
出版物
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 18, Issue 9, Pages 1049-1063
出版商
Informa Healthcare
发表日期
2014-06-26
DOI
10.1517/14728222.2014.934225
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Oxidative stress and schizophrenia
- (2014) Francesco E. Emiliani et al. CURRENT OPINION IN PSYCHIATRY
- A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia – Results from the CandleLyte study
- (2014) D. Bugarski-Kirola et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Prevention: Before the break
- (2014) Michele Solis NATURE
- Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: A systematic review of biomarker studies
- (2014) M.J. Stuart et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Clinically meaningful biomarkers for psychosis: A systematic and quantitative review
- (2014) Diana Prata et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Abnormalities of the glutamine–glutamate–GABA cycle in the schizophrenia brain
- (2014) Kenji Hashimoto SCHIZOPHRENIA RESEARCH
- N-acetylcysteine prevents increased amphetamine sensitivity in social isolation-reared mice
- (2014) Ana P. Herrmann et al. SCHIZOPHRENIA RESEARCH
- Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia
- (2014) Daniel Umbricht et al. JAMA Psychiatry
- Bitopertin
- (2014) Donald C. Goff JAMA Psychiatry
- Increased Glutamine in Patients Undergoing Long-term Treatment for Schizophrenia
- (2014) Juan R. Bustillo et al. JAMA Psychiatry
- N-Acetylcysteine as an Adjunct to Risperidone for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia
- (2013) Mehdi Farokhnia et al. CLINICAL NEUROPHARMACOLOGY
- D-Amino Acid Oxidase Inhibitors as a Novel Class of Drugs for Schizophrenia Therapy
- (2013) Silvia Sacchi et al. CURRENT PHARMACEUTICAL DESIGN
- Biomarkers in Schizophrenia: A Brief Conceptual Consideration
- (2013) Cynthia S. Weickert et al. DISEASE MARKERS
- Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders
- (2013) Kenji Hashimoto et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
- N-Acetylcysteine amide: a derivative to fulfill the promises of N-Acetylcysteine
- (2013) K. Sunitha et al. FREE RADICAL RESEARCH
- Up-Regulation of Neurotrophic Factors by Cinnamon and its Metabolite Sodium Benzoate: Therapeutic Implications for Neurodegenerative Disorders
- (2013) Arundhati Jana et al. Journal of Neuroimmune Pharmacology
- Disruption of Shmt1 Impairs Hippocampal Neurogenesis and Mnemonic Function in Mice
- (2013) Elena V. Abarinov et al. JOURNAL OF NUTRITION
- Imaging glutamate in schizophrenia: review of findings and implications for drug discovery
- (2013) E M P Poels et al. MOLECULAR PSYCHIATRY
- Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals
- (2013) C-H Lin et al. MOLECULAR PSYCHIATRY
- Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: Reversal with galantamine
- (2013) K.S. Alexander et al. NEUROSCIENCE
- Neonatal Disruption of Serine Racemase Causes Schizophrenia-Like Behavioral Abnormalities in Adulthood: Clinical Rescue by D-Serine
- (2013) Hiroko Hagiwara et al. PLoS One
- Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With Schizophrenia: An Update
- (2013) I. E. Sommer et al. SCHIZOPHRENIA BULLETIN
- Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo
- (2013) Virginia L. Stauffer et al. SCHIZOPHRENIA RESEARCH
- The promise of N-acetylcysteine in neuropsychiatry
- (2013) Michael Berk et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Add-on Treatment of Benzoate for Schizophrenia
- (2013) Hsien-Yuan Lane et al. JAMA Psychiatry
- Redox Dysregulation in the Pathophysiology of Schizophrenia and Bipolar Disorder: Insights from Animal Models
- (2012) Anita Kulak et al. ANTIOXIDANTS & REDOX SIGNALING
- The Cystine/Glutamate Antiporter System xc− in Health and Disease: From Molecular Mechanisms to Novel Therapeutic Opportunities
- (2012) Jan Lewerenz et al. ANTIOXIDANTS & REDOX SIGNALING
- N-Acetylcysteine ethyl ester (NACET): A novel lipophilic cell-permeable cysteine derivative with an unusual pharmacokinetic feature and remarkable antioxidant potential
- (2012) Daniela Giustarini et al. BIOCHEMICAL PHARMACOLOGY
- Is D-Cycloserine a Prodrug for D-Serine in the Brain?
- (2012) Mao Horio et al. BIOLOGICAL PSYCHIATRY
- Early-Life Insults Impair Parvalbumin Interneurons via Oxidative Stress: Reversal by N-Acetylcysteine
- (2012) Jan-Harry Cabungcal et al. BIOLOGICAL PSYCHIATRY
- Can the Sigma-1 Receptor Agonist Fluvoxamine Prevent Schizophrenia?
- (2012) Kenji Hashimoto CNS & Neurological Disorders-Drug Targets
- Genetic Data Supporting the NMDA Glutamate Receptor Hypothesis for Schizophrenia
- (2012) Thomas L. Schwartz et al. CURRENT PHARMACEUTICAL DESIGN
- Sigma-1 Receptor Agonists as Therapeutic Drugs for Cognitive Impairment in Neuropsychiatric Diseases
- (2012) Tomihisa Niitsu et al. CURRENT PHARMACEUTICAL DESIGN
- Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia
- (2012) C S Weickert et al. MOLECULAR PSYCHIATRY
- Kynurenines in the mammalian brain: when physiology meets pathology
- (2012) Robert Schwarcz et al. NATURE REVIEWS NEUROSCIENCE
- Glycine Transporter Type 1 Occupancy by Bitopertin: a Positron Emission Tomography Study in Healthy Volunteers
- (2012) Meret Martin-Facklam et al. NEUROPSYCHOPHARMACOLOGY
- Glutathione Precursor N-Acetyl-Cysteine Modulates EEG Synchronization in Schizophrenia Patients: A Double-Blind, Randomized, Placebo-Controlled Trial
- (2012) Cristian Carmeli et al. PLoS One
- Role of Serine Racemase in Behavioral Sensitization in Mice after Repeated Administration of Methamphetamine
- (2012) Mao Horio et al. PLoS One
- Sigma-1 receptor chaperone and brain-derived neurotrophic factor: Emerging links between cardiovascular disease and depression
- (2012) Kenji Hashimoto PROGRESS IN NEUROBIOLOGY
- N-acetylcysteine as a potentially useful medication to prevent conversion to schizophrenia in at-risk individuals
- (2012) Elson Asevedo et al. REVIEWS IN THE NEUROSCIENCES
- Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia
- (2012) D. C. Javitt et al. SCHIZOPHRENIA BULLETIN
- NMDA Receptor and Schizophrenia: A Brief History
- (2012) J. T. Coyle SCHIZOPHRENIA BULLETIN
- Plasma levels of D-serine in Brazilian individuals with schizophrenia
- (2012) Marilia A. Calcia et al. SCHIZOPHRENIA RESEARCH
- Effects of the Antioxidant Sulforaphane on Hyperlocomotion and Prepulse Inhibition Deficits in Mice after Phencyclidine Administration
- (2012) Yumi Shirai et al. Clinical Psychopharmacology and Neuroscience
- Downregulated Kynurenine 3-Monooxygenase Gene Expression and Enzyme Activity in Schizophrenia and Genetic Association With Schizophrenia Endophenotypes
- (2011) Ikwunga Wonodi ARCHIVES OF GENERAL PSYCHIATRY
- Glutamatergic Modulation of Auditory Information Processing in the Human Brain
- (2011) Handan Gunduz-Bruce et al. BIOLOGICAL PSYCHIATRY
- N-Acetylcysteine Normalizes Neurochemical Changes in the Glutathione-Deficient Schizophrenia Mouse Model During Development
- (2011) Joao Miguel das Neves Duarte et al. BIOLOGICAL PSYCHIATRY
- α7 Nicotinic Acetylcholine Receptor as a Potential Therapeutic Target for Schizophrenia
- (2011) Masatomo Ishikawa et al. CURRENT PHARMACEUTICAL DESIGN
- Recent Advances in the Discovery of D-Amino Acid Oxidase Inhibitors and Their Therapeutic Utility in Schizophrenia
- (2011) Dana V. Ferraris et al. CURRENT PHARMACEUTICAL DESIGN
- Glycine Transporter-1: A New Potential Therapeutic Target for Schizophrenia
- (2011) Kenji Hashimoto et al. CURRENT PHARMACEUTICAL DESIGN
- Kynurenine Pathway in Schizophrenia: Pathophysiological and Therapeutic Aspects
- (2011) Norbert Muller et al. CURRENT PHARMACEUTICAL DESIGN
- Levels of d-serine in the brain and peripheral organs of serine racemase (Srr) knock-out mice
- (2011) Mao Horio et al. NEUROCHEMISTRY INTERNATIONAL
- Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia
- (2011) Daniela Alberati et al. NEUROPHARMACOLOGY
- From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment
- (2011) Bita Moghaddam et al. NEUROPSYCHOPHARMACOLOGY
- Protective effects of the antioxidant sulforaphane on behavioral changes and neurotoxicity in mice after the administration of methamphetamine
- (2011) Hongxian Chen et al. PSYCHOPHARMACOLOGY
- Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine
- (2011) Kathleen S. Alexander et al. PSYCHOPHARMACOLOGY
- Translating Glutamate: From Pathophysiology to Treatment
- (2011) D. C. Javitt et al. Science Translational Medicine
- Magnetic Resonance Spectroscopy Study of the Antioxidant Defense System in Schizophrenia
- (2010) Daisuke Matsuzawa et al. ANTIOXIDANTS & REDOX SIGNALING
- Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders
- (2010) G. Paul Amminger et al. ARCHIVES OF GENERAL PSYCHIATRY
- Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis
- (2010) Guochuan Tsai et al. CURRENT PHARMACEUTICAL DESIGN
- Selective GlyT1 Inhibitors: Discovery of [4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a Promising Novel Medicine To Treat Schizophrenia
- (2010) Emmanuel Pinard et al. JOURNAL OF MEDICINAL CHEMISTRY
- Analysis of strain-dependent prepulse inhibition points to a role for Shmt1 (SHMT1) in mice and in schizophrenia
- (2010) Motoko Maekawa et al. JOURNAL OF NEUROCHEMISTRY
- Redox Dysregulation Affects the Ventral But Not Dorsal Hippocampus: Impairment of Parvalbumin Neurons, Gamma Oscillations, and Related Behaviors
- (2010) P. Steullet et al. JOURNAL OF NEUROSCIENCE
- Glutamate Receptor Ion Channels: Structure, Regulation, and Function
- (2010) S. F. Traynelis et al. PHARMACOLOGICAL REVIEWS
- Brain-derived neurotrophic factor as a biomarker for mood disorders: An historical overview and future directions
- (2010) Kenji Hashimoto PSYCHIATRY AND CLINICAL NEUROSCIENCES
- Impaired Kynurenine Pathway Metabolism in The Prefrontal Cortex of Individuals With Schizophrenia
- (2010) K. V. Sathyasaikumar et al. SCHIZOPHRENIA BULLETIN
- Developmental Vitamin D Deficiency and Risk of Schizophrenia: A 10-Year Update
- (2010) J. J. McGrath et al. SCHIZOPHRENIA BULLETIN
- High dose D-serine in the treatment of schizophrenia
- (2010) Joshua T. Kantrowitz et al. SCHIZOPHRENIA RESEARCH
- Co-Administration of a D-Amino Acid Oxidase Inhibitor Potentiates the Efficacy of D-Serine in Attenuating Prepulse Inhibition Deficits After Administration of Dizocilpine
- (2009) Kenji Hashimoto et al. BIOLOGICAL PSYCHIATRY
- A randomized, double-blind, placebo-controlled comparison study of sarcosine ( N-methylglycine) and d-serine add-on treatment for schizophrenia
- (2009) Hsien-Yuan Lane et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- NMDA- and -Amyloid1-42-Induced Neurotoxicity Is Attenuated in Serine Racemase Knock-Out Mice
- (2009) R. Inoue et al. JOURNAL OF NEUROSCIENCE
- Comments on ‘The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia’
- (2009) Kenji Hashimoto JOURNAL OF PSYCHOPHARMACOLOGY
- The neurobiology of D-amino acid oxidase and its involvement in schizophrenia
- (2009) L Verrall et al. MOLECULAR PSYCHIATRY
- Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
- (2009) Arun Sreekumar et al. NATURE
- Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: A preliminary study
- (2009) Yukihiko Shirayama et al. NEUROIMAGE
- Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients
- (2009) Monia Raffa et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Regarding “N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia—A Double-Blind, Randomized, Placebo-Controlled Trial”
- (2008) Kenji Hashimoto BIOLOGICAL PSYCHIATRY
- N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia—A Double-Blind, Randomized, Placebo-Controlled Trial
- (2008) Michael Berk et al. BIOLOGICAL PSYCHIATRY
- Synthesis and Biological Evaluation ofd-Amino Acid Oxidase Inhibitors
- (2008) Dana Ferraris et al. JOURNAL OF MEDICINAL CHEMISTRY
- Medial temporal lobe glutathione concentration in first episode psychosis: A 1H-MRS investigation
- (2008) Stephen J. Wood et al. NEUROBIOLOGY OF DISEASE
- Negative Correlation between Brain Glutathione Level and Negative Symptoms in Schizophrenia: A 3T 1H-MRS Study
- (2008) Daisuke Matsuzawa et al. PLoS One
- d-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats
- (2007) Jun-ichi Karasawa et al. BEHAVIOURAL BRAIN RESEARCH
- Sarcosine (N-Methylglycine) Treatment for Acute Schizophrenia: A Randomized, Double-Blind Study
- (2007) Hsien-Yuan Lane et al. BIOLOGICAL PSYCHIATRY
- Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and d-serine
- (2007) Kenji Hashimoto et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Neurophysiological biomarkers for drug development in schizophrenia
- (2007) Daniel C. Javitt et al. NATURE REVIEWS DRUG DISCOVERY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started